AstraZeneca Pharmaceuticals has voluntarily recalled 916 units of Fasenra (benralizumab) Injection, 30 mg/mL, because there is a lack of assurance regarding the product's sterility. Fasenra is a prescription medication provided in a single-dose pre-filled syringe for the treatment of severe asthma. This recall affects a specific production lot (YJ0152) distributed nationwide across the United States. If you are a patient using this medication, you should contact your healthcare provider or pharmacist immediately to discuss your treatment options and ensure you have a safe supply.
A lack of sterility assurance means the medication may not be free from microorganisms, which can lead to serious or life-threatening infections if injected into the body. No injuries or adverse events have been reported to date, but the risk remains significant for a sterile injectable product.
You have 2 options:
Recall #: D-0028-2026; Quantity: 916 pre-filled syringes; Manufactured by AstraZeneca AB, Sweden.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.